Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancerLuca Gianni, Giuseppe Viale, Antonio Frassoldati et al.|npj Breast Cancer|2022Cited by 29
Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.Luca Gianni, Giuseppe Viale, Marco Colleoni et al.|Journal of Clinical Oncology|2019Cited by 7
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapiesMaurizio Callari, Giampaolo Bianchini, Matteo Dugo et al.|Nature Communications|2025Cited by 5
ER and immune-related signatures define benefit to palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ breast cancer patients in the NA-PHER2 trial.Giampaolo Bianchini, Luca Gianni, Matteo Dugo et al.|Journal of Clinical Oncology|2021Cited by 1